Results of genotyping for the G-CSF-R_Glu785Lys polymorphism in MDS, de novo AML patients, and matched healthy controls
. | Total no. . | 785Glu/Glu, no. (%) . | 785Glu/Lys, no. (%) . | P versus controls . | Odds ratio versus controls (95% CI) . |
|---|---|---|---|---|---|
| Controls | 232 | 230 (99.1) | 2 (0.9) | NA | NA |
| MDS patients | 116 | 108 (93.1) | 8 (6.9) | .003 | 8.5 (1.8-40.7) |
| Low-risk MDS | 44 | 43 (97.7) | 1 (2.3) | .407 | ND |
| High-risk MDS | 72 | 65 (90.3) | 7 (9.7) | .001 | 12.5 (2.4-58.9) |
| IPSS low-risk MDS | 51 | 50 (98.0) | 1 (2.0) | .45 | ND |
| IPSS high-risk MDS | 54 | 47 (87.0) | 7 (13.0) | < .001 | 14.0 (3.4-85.0) |
| De novo AML | 84 | 82 (97.6) | 2 (2.4) | .288 | ND |
. | Total no. . | 785Glu/Glu, no. (%) . | 785Glu/Lys, no. (%) . | P versus controls . | Odds ratio versus controls (95% CI) . |
|---|---|---|---|---|---|
| Controls | 232 | 230 (99.1) | 2 (0.9) | NA | NA |
| MDS patients | 116 | 108 (93.1) | 8 (6.9) | .003 | 8.5 (1.8-40.7) |
| Low-risk MDS | 44 | 43 (97.7) | 1 (2.3) | .407 | ND |
| High-risk MDS | 72 | 65 (90.3) | 7 (9.7) | .001 | 12.5 (2.4-58.9) |
| IPSS low-risk MDS | 51 | 50 (98.0) | 1 (2.0) | .45 | ND |
| IPSS high-risk MDS | 54 | 47 (87.0) | 7 (13.0) | < .001 | 14.0 (3.4-85.0) |
| De novo AML | 84 | 82 (97.6) | 2 (2.4) | .288 | ND |
Subclassification of MDS patients was done using the percentage of BM blasts (low-risk group: less than 5% BM blasts, patients with RA and RARS; high-risk group: more than 5% BM blasts, patients with RAEB, RAEBt, and secondary AML following MDS) and using the IPSS (low-risk group: a low or intermediate-1 score; high- risk group: an intermediate-2 or higher score). Due to lack of information on cytogenetic abnormalities in 11 MDS patients, scoring with the IPSS was possible for only 105 patients. Genotype distribution was assessed for significance using the Fisher exact test. Odds ratios and 95% confidence intervals (95% CI) were calculated by logistic regression analysis.
NA indicates not applicable; ND, not done.